Amneal Biosciences
pipeline
The future of accessible medicine
Over 30 new injectable medicines are coming
With 3 FDA-approved biosimilars in the market and more on the way, Amneal Biosciences is investing boldly in growing these therapeutic offerings. In addition, Amneal is proud to launch a pipeline of evolved formulations of prescriber-administered oncology therapies through the 505(b)(2) approval pathway. This pathway allows for changes in product characteristics that may support operational efficiency, such as simplified storage and preparation.
Amneal Biosciences’ products in the United States
2022
(launched)
ALYMSYS® (bevacizumab-maly)
RELEUKO® (filgrastim-ayow)
2023
(launched)
FYLNETRA® (pegfilgrastim-pbbk)
2024
(launched)
PEMRYDI RTU® (pemetrexed injection)
FOCINVEZ™ (fosaprepitant injection)
2025
(launched)
BORUZU® (bortezomib injection)
(anticipated launch)
15 new generic injectables
2026
(anticipated launch)
FYLNETRA® On-Body Injector (pegfilgrastim-pbbk)
FYLNETRA® Autoinjector (pegfilgrastim-pbbk)
Denosumab – oncology
Denosumab – osteoporosis
15-20 new generic injectables
2027
(anticipated launch)
Omalizumab – immunology & inflammation
Our commitment is to become one of the leading biosimilar companies in the US through our current portfolio and future product launches.
— Scott Spencer
VP, Branded Institutional Sales & Marketing
